Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Latanoprost; Ophthalmic Solutions; Tetrahydrozoline; Travoprost

Criteria

Inclusion Criteria:

• Diagnosis of open-angle glaucoma (pseudoexfoliative or pigmentary glaucomas are allowed) or ocular hypertension

Exclusion Criteria:

• Known contraindication to latanoprost, bimatoprost or travoprost

• Uncontrolled systemic disease

• Active ocular disease other than glaucoma or ocular hypertension

• Pregnant or lactating women or women of childbearing potential NOT utilizing a medically acceptable form of birth control